Sei Investments Co. Takes $992,000 Position in Disc Medicine, Inc. $IRON

Sei Investments Co. purchased a new stake in Disc Medicine, Inc. (NASDAQ:IRON) during the first quarter, Holdings Channel reports. The institutional investor purchased 15,510 shares of the company’s stock, valued at approximately $992,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. RA Capital Management L.P. grew its holdings in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares during the period. Vanguard Group Inc. raised its holdings in Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Disc Medicine by 7.7% in the 4th quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock valued at $120,566,000 after buying an additional 108,197 shares during the period. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Morgan Stanley upped their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Wedbush reaffirmed an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, HC Wainwright lifted their price objective on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $106.00.

Disc Medicine Stock Down 0.8%

Shares of IRON stock opened at $80.59 on Thursday. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The firm’s fifty day moving average price is $74.19 and its two-hundred day moving average price is $69.87. The firm has a market capitalization of $3.09 billion, a P/E ratio of -12.25 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. On average, equities analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 33,000 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the transaction, the chief executive officer owned 226,064 shares of the company’s stock, valued at $16,945,757.44. The trade was a 12.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Rahul Khara sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the sale, the insider directly owned 52,324 shares of the company’s stock, valued at approximately $4,185,920. The trade was a 8.72% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 110,712 shares of company stock worth $7,997,536. Corporate insiders own 3.76% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.